This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Sk Biopharmaceuticals Co., Ltd., Sk Holdings Co., Ltd.. Active years: 2011-2013.
Company Filing History:
Years Active: 2011-2013
Title: Tae Sung Koo: Innovator in Pharmaceutical Composition
Introduction
Tae Sung Koo is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at preventing and treating vascular restenosis. With a total of 2 patents, his work showcases innovative approaches to medical challenges.
Latest Patents
One of his latest patents is a pharmaceutical composition for the prevention and treatment of restenosis comprising isoxazole derivatives. This composition includes a therapeutically effective amount of isoxazole derivatives, which are believed to show anti-restenosis activity and accelerate re-endothelization. Another notable patent involves isoxazole derivatives that serve as agonists of Wnt, activating Wnt/β-catenin signaling. This innovation can be utilized in the treatment and prevention of diseases related to signal transduction.
Career Highlights
Throughout his career, Tae Sung Koo has worked with notable companies such as SK Holdings Co., Ltd. and SK Biopharmaceuticals Co., Ltd. His experience in these organizations has allowed him to contribute to significant advancements in pharmaceutical research and development.
Collaborations
Tae Sung Koo has collaborated with esteemed colleagues, including Sung Jin Bae and Sang Rak Choi. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical sector.
Conclusion
Tae Sung Koo's contributions to pharmaceutical compositions demonstrate his commitment to addressing critical medical issues. His innovative work in isoxazole derivatives highlights the potential for advancements in treatment options for vascular conditions.